| I. COMMENCED TRADING IN NOVEMBER | ||||||||
| INITIAL OFFERINGS | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M)% |
| There were no initial public offerings conducted in November. | ||||||||
| Total: $0M | ||||||||
| Number of IPOs in November: 0 | ||||||||
| Average value of November IPOs: $0M | ||||||||
| Number of IPOs in 2008: 3 | ||||||||
| Total raised in IPOs in 2008: $93.7M | ||||||||
| Average value of IPOs in 2008: $31.2M | ||||||||
| FOLLOW-ON OFFERINGS | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (M) | Post-Offering Market Cap (M)% |
| There were no follow-on public offerings conducted in November. | ||||||||
| Total: $0M | ||||||||
| Number of follow-on offerings in November: 0 | ||||||||
| Average value of November follow-ons: $0M | ||||||||
| Number of follow-on offerings in 2008: 20 | ||||||||
| Total raised in follow-ons in 2008: $2,155.61M | ||||||||
| Average value of follow-ons in 2008: $107.78M | ||||||||
| Notes: | ||||||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
| @ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
| % Market capitalization is calculated based on the offering price. | ||||||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||||||
| II. FILED AND PENDING | ||||||
| Company (Symbol/Proposed Symbol)#* | Date Filed | Shares/Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) |
| INITIAL OFFERINGS | ||||||
| Aegerion Pharmaceuticals Inc. (AEGR) | 11/21/07 | N/A | N/A | N/A | Piper Jaffray Thomas Weisel Partners (co-lead) Lazard Capital Markets Collins Stewart LLC |
$86 |
| Alimera Sciences Inc. (ALIM) | 7/2/08 | N/A | N/A | N/A | Credit Suisse Sec. Citigroup Cowen & Co. Leerink Swann LLC |
$75 |
| Anacor Pharmaceuticals Inc. (ANAC) | 8/31/07 | N/A | N/A | N/A | Morgan Stanley & Co. Inc. Cowen & Co. LLC (co-lead) Pacific Growth Equities LLC Needham & Co. LLC |
$57.5 |
| BioTrove Inc. (BTRV) | 4/1/08 | N/A | N/A | N/A | Piper Jaffray & Co. Lazard Capital Markets (co-lead) Robert W. Baird & Co. |
$75 |
| Chemocentryx Inc. (CCXI) | 11/12/07 | N/A | N/A | N/A | Credit Suisse Securities LLC Cowen and Co. Leerink Swann Lazard Capital Markets |
$57.5 |
| Omeros Corp. (OMER) | 1/10/08 | N/A | N/A | N/A | Deutsche Bank Securities Pacific Growth Equities Leerink Swann LLC Needham & Co. LLC |
$115 |
| Prometheus Laboratories Inc. (RXDX) | 12/19/07 | N/A | N/A | N/A | Goldman Sachs & Co. Credit Suisse (co-lead) Banc of America Securities Cowen & Co. Pacific Growth Equities LLC |
$100 |
| Notes: | ||||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
| The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. | ||||||
| N/A = Not available, applicable or reported | ||||||